A Northumberland rare cancer research startup has closed a £340,000 seed funding round which will help the business to move to the next phase of its development.
RareCan, based in Hexham, champions the view that those with rare forms of cancer should have the same opportunities in treatments and research as those with more common forms. Rare cancer affects more than 70,000 people per year in the UK – more than one in five of the total – and about two thirds will die from the disease within five years, as compared with under half for more common cancers.
The organisation brings patients together, helping them make their data available to researchers, to help speed up the effective development of treatments and diagnostics.
